Kim Bohye, Weon Boram, Kim Evonne, Park Sohee, Jin Wencheng, Shin Nayeon, Oh Yun Kyu, Lim Chun Soo, Lee Jung Pyo, Kwon Obin, Lee Jeonghwan
Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul, South Korea.
Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, South Korea.
Heliyon. 2025 Feb 1;11(3):e42416. doi: 10.1016/j.heliyon.2025.e42416. eCollection 2025 Feb 15.
Multiciliated cells (MCCs) have been identified in the proximal tubules of patients with kidney disease; however, their clinical significance is unknown. We aimed to investigate whether MCCs are associated with clinical outcomes in patients with glomerular diseases.
Between August 2012 and April 2021, 134 patients (including 126 with glomerular disease patients and 8 controls) who were hospitalized at Seoul National University Boramae Medical Center and Seoul National University Hospital were included in this study. The ratio of MCCs to total proximal tubular cells was calculated using immunohistochemistry. The relationship between the MCC ratio and kidney disease-related clinical features was then analyzed.
MCCs were exclusively detected in patients with glomerular diseases (68.3 %), not those in the control group. Patients with diabetic kidney disease (88.9 %) or antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN, 86.4 %) had higher MCC ratios. MCC-positivity and MCC ratios were significantly associated with increased age and proteinuria, and a decreased estimated glomerular filtration rate (eGFR). Patients with higher MCC ratios had a significantly higher risk of end-stage kidney disease (ESKD) and composite outcomes with death. In multivariable analysis, MCC ratios were significantly correlated with an increased risk of ESKD (hazard ratio [HR], 1.413; 95 % confidence interval [CI], 1.012-1.972) and composite outcome (HR, 1.401; 95 % CI, 1.028-1.909).
Higher MCC ratios were correlated with poorer prognosis; therefore, quantification of MCCs in the proximal tubules can serve as a valuable prognostic marker in clinical practice.
在肾病患者的近端小管中已发现多纤毛细胞(MCCs);然而,它们的临床意义尚不清楚。我们旨在研究MCCs是否与肾小球疾病患者的临床结局相关。
2012年8月至2021年4月期间,本研究纳入了134名在首尔国立大学保罗马医院和首尔国立大学医院住院的患者(包括126名肾小球疾病患者和8名对照)。使用免疫组织化学计算MCCs与总近端小管细胞的比例。然后分析MCC比例与肾病相关临床特征之间的关系。
仅在肾小球疾病患者(68.3%)中检测到MCCs,对照组未检测到。糖尿病肾病患者(88.9%)或抗中性粒细胞胞浆抗体(ANCA)相关肾小球肾炎(GN,86.4%)患者的MCC比例更高。MCC阳性和MCC比例与年龄增加、蛋白尿以及估计肾小球滤过率(eGFR)降低显著相关。MCC比例较高的患者发生终末期肾病(ESKD)和复合死亡结局的风险显著更高。在多变量分析中,MCC比例与ESKD风险增加(风险比[HR],1.413;95%置信区间[CI],1.012 - 1.972)和复合结局(HR,1.401;95%CI,1.028 - 1.909)显著相关。
较高的MCC比例与较差的预后相关;因此,近端小管中MCCs的定量可作为临床实践中有价值的预后标志物。